TNF Pharmaceuticals (LTS:0A8D) Total Equity : $14.72 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is TNF Pharmaceuticals Total Equity?

TNF Pharmaceuticals's total equity for the quarter that ended in Dec. 2024 was $14.72 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

TNF Pharmaceuticals Total Equity Historical Data

The historical data trend for TNF Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TNF Pharmaceuticals Total Equity Chart

TNF Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Total Equity

-5.26

23.65

14.70

12.77

14.72

TNF Pharmaceuticals Quarterly Data
	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Equity	Get a 7-Day Free Trial														12.77	10.24	0.38	17.06	14.72

TNF Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

TNF Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	21.421	-	6.701
	=	14.72

TNF Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2024 )	-	Total Liabilities(Q: Dec. 2024 )
	=	21.421	-	6.701
	=	14.72

TNF Pharmaceuticals Total Equity Related Terms

Thank you for viewing the detailed overview of TNF Pharmaceuticals's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

TNF Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TNF Pharmaceuticals Inc (LTS:0A8D) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

TNFA:USA

Address

855 North Wolfe Street, Suite 601, Baltimore, MD, USA, 21205

Website

https://tnfpharma.com

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

TNF Pharmaceuticals Headlines

No Headlines